| Belayet Hossain, MD | |
|
5401 S Congress Ave, # 204, Atlantis, FL 33462-6635 | |
| (561) 967-4118 | |
| (561) 967-3463 |
| Full Name | Belayet Hossain |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 41 Years |
| Location | 5401 S Congress Ave, Atlantis, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619914868 | NPI | - | NPPES |
| 261162700 | Medicaid | FL | |
| 05285 | Other | FL | BLUE CROSS BLUE SHIELD |
| 279226 | Other | FL | WELLCARE |
| P00312911 | Other | FL | RAILROAD MEDICARE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Palms West Hospital | Loxahatchee, FL | Hospital |
| Jupiter Medical Center | Jupiter, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intensive Care Consortium Inc | 0244269413 | 370 |
| Nuview Telehealth Llc | 8022166974 | 60 |
News Archive
Monsanto Company (NYSE:MON) today announced a non-exclusive research and commercial license agreement with France-based Cellectis S.A. (Paris:ALCLS), a biotechnology company specialized in genome engineering, for broad use of its meganuclease technology in plants.
In science, refuting a hypothesis can be as significant as proving one, all the more so in research aimed at elucidating how diseases proceed with a view toward preventing, treating, or curing them. Such a discovery can save scientists from spending precious years of effort exploring a dead end. In a study published in the Proceedings of the National Academy of Sciences, Munich-based researchers refute a widely accepted hypothesis about a causative step in neurodegenerative conditions.
Researchers at Mayo Clinic have narrowed the search for effective prostate cancer biomarkers (genetic variations that point to a specific disease or condition), identifying changes in the expression of genes of the whole genome closely correlated to prostate cancer development and progression.
Specially tailored, ultrafast pulses of light can trigger neurons to fire and could one day help patients with light-sensitive circadian or mood problems, according to a new study in mice at the University of Illinois.
› Verified 9 days ago
| Entity Name | Intensive Care Consortium Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629019062 PECOS PAC ID: 0244269413 Enrollment ID: O20050808000883 |
News Archive
Monsanto Company (NYSE:MON) today announced a non-exclusive research and commercial license agreement with France-based Cellectis S.A. (Paris:ALCLS), a biotechnology company specialized in genome engineering, for broad use of its meganuclease technology in plants.
In science, refuting a hypothesis can be as significant as proving one, all the more so in research aimed at elucidating how diseases proceed with a view toward preventing, treating, or curing them. Such a discovery can save scientists from spending precious years of effort exploring a dead end. In a study published in the Proceedings of the National Academy of Sciences, Munich-based researchers refute a widely accepted hypothesis about a causative step in neurodegenerative conditions.
Researchers at Mayo Clinic have narrowed the search for effective prostate cancer biomarkers (genetic variations that point to a specific disease or condition), identifying changes in the expression of genes of the whole genome closely correlated to prostate cancer development and progression.
Specially tailored, ultrafast pulses of light can trigger neurons to fire and could one day help patients with light-sensitive circadian or mood problems, according to a new study in mice at the University of Illinois.
› Verified 9 days ago
| Entity Name | Nuview Telehealth Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538300181 PECOS PAC ID: 8022166974 Enrollment ID: O20090501000425 |
News Archive
Monsanto Company (NYSE:MON) today announced a non-exclusive research and commercial license agreement with France-based Cellectis S.A. (Paris:ALCLS), a biotechnology company specialized in genome engineering, for broad use of its meganuclease technology in plants.
In science, refuting a hypothesis can be as significant as proving one, all the more so in research aimed at elucidating how diseases proceed with a view toward preventing, treating, or curing them. Such a discovery can save scientists from spending precious years of effort exploring a dead end. In a study published in the Proceedings of the National Academy of Sciences, Munich-based researchers refute a widely accepted hypothesis about a causative step in neurodegenerative conditions.
Researchers at Mayo Clinic have narrowed the search for effective prostate cancer biomarkers (genetic variations that point to a specific disease or condition), identifying changes in the expression of genes of the whole genome closely correlated to prostate cancer development and progression.
Specially tailored, ultrafast pulses of light can trigger neurons to fire and could one day help patients with light-sensitive circadian or mood problems, according to a new study in mice at the University of Illinois.
› Verified 9 days ago
| Entity Name | Accountable Critical Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265897706 PECOS PAC ID: 3971801622 Enrollment ID: O20160412002606 |
News Archive
Monsanto Company (NYSE:MON) today announced a non-exclusive research and commercial license agreement with France-based Cellectis S.A. (Paris:ALCLS), a biotechnology company specialized in genome engineering, for broad use of its meganuclease technology in plants.
In science, refuting a hypothesis can be as significant as proving one, all the more so in research aimed at elucidating how diseases proceed with a view toward preventing, treating, or curing them. Such a discovery can save scientists from spending precious years of effort exploring a dead end. In a study published in the Proceedings of the National Academy of Sciences, Munich-based researchers refute a widely accepted hypothesis about a causative step in neurodegenerative conditions.
Researchers at Mayo Clinic have narrowed the search for effective prostate cancer biomarkers (genetic variations that point to a specific disease or condition), identifying changes in the expression of genes of the whole genome closely correlated to prostate cancer development and progression.
Specially tailored, ultrafast pulses of light can trigger neurons to fire and could one day help patients with light-sensitive circadian or mood problems, according to a new study in mice at the University of Illinois.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Belayet Hossain, MD Po Box 266211, Weston, FL 33326-6211 Ph: (567) 967-4115 | Belayet Hossain, MD 5401 S Congress Ave, # 204, Atlantis, FL 33462-6635 Ph: (561) 967-4118 |
News Archive
Monsanto Company (NYSE:MON) today announced a non-exclusive research and commercial license agreement with France-based Cellectis S.A. (Paris:ALCLS), a biotechnology company specialized in genome engineering, for broad use of its meganuclease technology in plants.
In science, refuting a hypothesis can be as significant as proving one, all the more so in research aimed at elucidating how diseases proceed with a view toward preventing, treating, or curing them. Such a discovery can save scientists from spending precious years of effort exploring a dead end. In a study published in the Proceedings of the National Academy of Sciences, Munich-based researchers refute a widely accepted hypothesis about a causative step in neurodegenerative conditions.
Researchers at Mayo Clinic have narrowed the search for effective prostate cancer biomarkers (genetic variations that point to a specific disease or condition), identifying changes in the expression of genes of the whole genome closely correlated to prostate cancer development and progression.
Specially tailored, ultrafast pulses of light can trigger neurons to fire and could one day help patients with light-sensitive circadian or mood problems, according to a new study in mice at the University of Illinois.
› Verified 9 days ago
James Heron, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5401 S Congress Ave, #218, Atlantis, FL 33462 Phone: 561-968-0307 Fax: 561-968-7673 | |
Roberto Von Sohsten, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5401 S Congress Ave, #102, Atlantis, FL 33462 Phone: 561-967-5033 Fax: 561-967-8974 | |
Dr. Samantha Sylvonne Kerry-ann Nicholson-spence, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-548-1273 | |
Alexander Chernobelsky, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5401 S Congress Ave, #102, Atlantis, FL 33462 Phone: 561-967-5033 Fax: 561-967-8974 | |
Denzil S Seedial, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5401 S Congress Ave, Ste 204, Atlantis, FL 33462 Phone: 561-967-4118 Fax: 561-967-3463 | |
Dr. Daphnee Marie Hutchinson, D.O. Internal Medicine Medicare: Medicare Enrolled Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-548-1750 | |
Dr. Farahnaz Angella, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 180 Jfk Dr, Suite 311, Atlantis, FL 33462 Phone: 561-434-0353 Fax: 561-357-0869 |